Log in

Relevant bibliographies by topics / Antineoplastic agents

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Antineoplastic agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antineoplastic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antineoplastic agents"

1

Carlson, Patricia A. "Antineoplastic agents." Critical Care Nursing Quarterly 18, no. 4 (February 1996): 1–15. http://dx.doi.org/10.1097/00002727-199602000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Menta, Ernesto, and Manlio Palumbo. "Novel antineoplastic agents." Expert Opinion on Therapeutic Patents 7, no. 12 (December 1997): 1401–26. http://dx.doi.org/10.1517/13543776.7.12.1401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Menta, Ernesto, and Manlio Palumbo. "Antineoplastic agents 1998." Expert Opinion on Therapeutic Patents 8, no. 12 (December 1998): 1627–72. http://dx.doi.org/10.1517/13543776.8.12.1627.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Pettit, G. R., Y. Kamano, R. Aoyagi, C. L. Herald, D. L. Doubek, J. M. Schmidt, and J. J. Rudloe. "Antineoplastic agents 100." Tetrahedron 41, no. 6 (January 1985): 985–94. http://dx.doi.org/10.1016/s0040-4020(01)96466-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bukowski, Ronald M. "Novel antineoplastic agents." Current Oncology Reports 2, no. 1 (January 2000): 9–10. http://dx.doi.org/10.1007/s11912-000-0004-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hong, Samuel J., Edward C. Li, Linda M. Matusiak, and Glen T. Schumock. "Spending on Antineoplastic Agents in the United States, 2011 to 2016." Journal of Oncology Practice 14, no. 11 (November 2018): e683-e691. http://dx.doi.org/10.1200/jop.18.00069.

Full text

Abstract:

Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of January 1, 2011, to December 31, 2016. Actual expenditures were totaled by health care sector and calendar year, then adjusted for medical-cost inflation to 2016 dollars. Growth was calculated as the percentage increase from the previous year. Results: Total expenditures of antineoplastic agents across all channels grew from $26.8 billion in 2011 to $42.1 billion in 2016. Antineoplastic spending increased 12.2% in 2016 (compared with the previous year), followed by 15.6% in 2015, 13.4% in 2014, 6.3% in 2013, and 0.4% in 2012. Throughout the study period, 96.5% of total antineoplastic expenditures occurred within clinics, mail-order pharmacies, nonfederal hospitals, and retail pharmacies. Conclusion: Antineoplastic expenditures are expected to increase because of continuing development and approval of costly targeted cancer therapies. Cost containment and utilization management strategies must be balanced so as not to restrict access or disrupt innovation. Future policies should focus on ensuring safe and appropriate use of antineoplastics while balancing long-term drug costs.

APA, Harvard, Vancouver, ISO, and other styles

7

DOLL, DONALD C., Q. SCOT RINGENBERG, and JOHN W. YARBRO. "Antineoplastic Agents and Pregnancy." Obstetrical & Gynecological Survey 45, no. 6 (June 1990): 376. http://dx.doi.org/10.1097/00006254-199006000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 605. Isoquinstatins." Journal of Natural Products 81, no. 3 (September 19, 2017): 451–57. http://dx.doi.org/10.1021/acs.jnatprod.7b00352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hussain, M. A. ha, A. N. toinette J. Wozniak, and M. A. rk B. Edelstein. "Neurotoxicity of antineoplastic agents." Critical Reviews in Oncology/Hematology 14, no. 1 (February 1993): 61–75. http://dx.doi.org/10.1016/1040-8428(93)90006-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Castells, M. "Hypersensitivity to Antineoplastic Agents." Current Pharmaceutical Design 14, no. 27 (September 1, 2008): 2892–901. http://dx.doi.org/10.2174/138161208786369803.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Antineoplastic agents"

1

Wan, Jung Wing. "Novel ether lipids as antineoplastic agents." Thesis, University of Southampton, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.242627.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Molyneux, Gemma. "Studies on the haemotoxicity of antineoplastic agents." Thesis, University College London (University of London), 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.435080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chen, Alina. "New polyamine analogues as potential antineoplastic agents." Scholarly Commons, 2000. https://scholarlycommons.pacific.edu/uop_etds/2680.

Full text

Abstract:

The naturally occurring polyamines play an essential role in cell growth and proliferation. The levels of polyamines have been shown to increase in rapidly proliferating cancer cells. Therefore, compounds that inhibit enzymes in polyamine biosynthetic pathway may have therapeutic potential. Compounds capable of providing both in vitro and in vivo inhibition of almost all enzymes in the polyamine biosynthetic pathway are known. An exception is the lack of an agent that inhibits spermidine/spermine N 1 -acetyltransferase (SSAT), the rate-limiting enzyme in the catabolism of polyamines. The design, synthesis and characterization of five new polyamine analogues as potential inhibitors of SSAT are presented. Three compounds, N 1 -[3-(propenamido) propyl]-1,4-diaminobutane dihydrochloride 5 , N 1 -[3-(maleimido)propyl]-1,4-diamino-butane dihydrochloride 7 and N 1 -[3-(2-bromoacetamido)propyl]-1,4-diaminobutane dihydrochloride 9 , were designed as active-site-directed affinity label inhibitors. Two compounds, N-[N-(5-acetamido-2-hydroxypentyl-3-aminopropyl)]-1,4-diaminobutane trihydrochloride 12 and N-[3-(2-hydroxyethylamino)propyl]-1,4-diaminobutane trihydrochloride 14 , were designed as transition state-like analogue inhibitors. These compounds were synthesized using one key intermediate, N-(3-aminopropyl)-N,N ′ -bis-(tert-butoxycarbonyl)-1,4-diaminobutane 3 . Three of these synthesized compounds, 5 , 7 and 12 were evaluated for their ability to inhibit SSAT. The enzyme used was a crude extract of human large cell undifferentiated lung carcinoma cell line NCI H157 cells. These synthetic analogues when tested against the crude enzyme extract at concentrations of 0.05, 0.1, 1 and 5 μM appeared to show no effects on the activity of SSAT.

APA, Harvard, Vancouver, ISO, and other styles

4

Ganley, Brian. "Investigations into the chemical mechanisms of biological activity by heterocyclic di-N-oxides and 1,2 benzodithiolan-3-one 1-oxides." free to MU campus, to others for purchase, 2000. http://wwwlib.umi.com/cr/mo/fullcit?p9999285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ramirez, Daniel A. Kane Robert R. "Synthesis of protected amino thymidines and new thiol derivatives of the vascular targeting agent combretastatin A-4." Waco, Tex. : Baylor University, 2006. http://hdl.handle.net/2104/5008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ganley, Brian Christopher. "Investigations into the chemical mechanisms of biological activity by heterocyclic di-N-oxides and 1,2 benzodithiolan-3-one 1-oxides /." free to MU campus, to others for purchase, 2000. http://wwwlib.umi.com/cr/mo/fullcit?p9999285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Reese, Michael. "Drug design (STAT5 modulators), development (Glyceollin I) and improvement (Esmolol Plus) /." Connect to full text in OhioLINK ETD Center, 2009. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=toledo1265033116.

Full text

Abstract:

Thesis (M.S.)--University of Toledo, 2009.
Typescript. "Submitted as partial fulfillment of the requirements for the Master of Science Degree in Medicinal Chemistry." "A thesis entitled"--at head of title. Bibliography: leaves 45-48.

APA, Harvard, Vancouver, ISO, and other styles

8

Kanyanda, Stonard Sofiel Elisa. "Screening of natural products and Alkylating agents for Antineoplastic Activity." Thesis, University of the Western Cape, 2007. http://etd.uwc.ac.za/index.php?module=etd&action=viewtitle&id=gen8Srv25Nme4_6433_1363357514.

Full text

Abstract:

Background and objectives: Apoptosis is a process in which a cell programmes its own death. It is a highly organized physiological mechanism in which injured or damaged cells are destroyed. Apart from physiological stimuli however, exogenous factors can induce apoptosis. Many anti-cancer drugs work by activating apoptosis in cancer cells. Natural substances have been found to have the ability to induce apoptosis in various tumour cells and these substances have been used as templates for the construction of
novel lead compounds in anticancer treatment. On the other hand, alkylating agents such as cisplatin, cis- [PtCl2 (NH3) 2] have been widely used as antineoplastic agents for a
wide variety of cancers including testicular, ovarian, neck and head cancers, amongst others. However, the use of cisplatin as an anticancer agent is limited due to toxicity and resistance problems. The aim of this present study was to screen the leaves of Rhus laevigata, a South African indigenous plant, for the presence of pro-apoptotic and
anti-proliferative natural compounds and also to screen newly synthesised palladium based complexes (15 and 57) and a platinum based complex (58) for their antineoplastic
activities tested against a panel of cell lines. Results. The results showed that crude methanol extracts from Rhus laevigata as well as the newly synthesised palladium based complexes (15 and 57) and a platinum based complex (58) induced apoptosis in the cell lines tested, as demonstrated by the externalization of phosphatidylserine, mitochondrial membrane permeabilization,caspase-3 activation, and DNA fragmentation. Caski (cervical cancer) and H157 (non small cell lung carcinoma) cell lines treated with the methanol extract from Rhus laevigata however, were more resistant to apoptosis induction. Among the metallocomplexes, complexes 15 and 57, palladium based complexes, were the most active. Conclusion: The methanol extract from the leaves of Rhus laevigata contain pro-apoptotic and antiproliferative natural compound(s), which need to be characterised and elucidated as they could provide the much-needed lead compounds in the fight against cancer. On the other hand the newly synthesized palladium complexes also need further evaluation to
see if they can be used as anticancer agents that can overcome the problems associated with cisplatin.

APA, Harvard, Vancouver, ISO, and other styles

9

Parker-, Johnson Kitani A. "An evaluation of novel antineoplastic agent on prostate cancer." DigitalCommons@Robert W. Woodruff Library, Atlanta University Center, 2003. http://digitalcommons.auctr.edu/dissertations/3074.

Full text

Abstract:

This study examines the effects of novel antineoplastic agents(isochalcones) on human metastatic prostate cancer cell lines by screening cells for their relative antiproliferative effects, measuring the protein expression levels of specific oncogenes by Western blotting, and evaluating an array of genes ( 5184) to determine possible mechanisms of action of these novel isochalcones. The array data were supported by real-time polymerase chain reaction (PCR) techniques. The antineoplastic agents were screened in human metastatic prostate cancer cell lines (LNCaP, DU145, PC-3, and MDA-PCa-2b) and non-cancerous prostate epithelial cell line PZ-HPV-7 in concentrations ranging from nanomolar to millimolar. The alamar blue exclusion dye assay, a redox indicator, was used to evaluate cell proliferation when compared to the untreated control. DJ52 demonstrated a growth inhibitory effect on LNCaP, PC-3, and DU145 cell lines at the micromolar concentration (p<0.05). Based on these data, 1 x 106 cells were treated, protein isolated, and expression levels of epidermal growth factor (EGF) and omithine decarboxylase (ODC) were measured and compared to theuntreated controls. These data indicated a dose-dependent decrease of expression of EGF and ODC, therefore, suggesting that other key oncogenes may also have a decrease in expression when treated with these novel antineoplastic agents. Therefore, gene arrays were used to identify possible families of genes and/or specific pathways that may be responsible for the antiproliferative effects noted. It was determined that the key families of genes significantly induced by these agents (Pathways 4®) were proapoptotic and cell cycle regulators. ABI 7700 Prism was used to perform quantitative RT-PCR via the AB Sequence Detector® software.

APA, Harvard, Vancouver, ISO, and other styles

10

Lin, Tung Yin. "Synthetic studies towards the stellettins /." View online, 2008. http://repository.eiu.edu/theses/docs/32211131443971.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Antineoplastic agents"

1

Milne, George W. A., 1937-, ed. Ashgate handbook of antineoplastic agents. Aldershot: Ashgate, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

David, Goldman I., ed. Membrane transport of antineoplastic agents. Oxford: Pergamon Press, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

1932-, Borders Donald B., and Doyle Terrence W. 1942-, eds. Enediyne antibiotics as antitumor agents. New York: M. Dekker, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

E, Wittes Robert, and National Cancer Institute (U.S.), eds. Compilation of phase II results with single antineoplastic agents. Bethesda, Md: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

V, Wilman Derry E., ed. The chemistry of antitumour agents. London: Blackie, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

David, Kessel, ed. Resistance to antineoplastic drugs. Boca Raton, Fla: CRC Press, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

A, Valeriote Frederick, Corbett Thomas H, and Baker Lawrence H, eds. Anticancer drug discovery and development: Natural products and new molecular models : proceedings of the Second Drug Discovery and Development Symposium, Traverse City, Michigan, USA, June 27-29, 1991. Boston: Kluwer Academic Publishers, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Chow, Nang-Ly. Liposomes as carriers of antineoplastic agents and immunomodulators. Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

National Institutes of Health (U.S.), ed. Compilation of phase II results with single antineoplastic agents. [Bethesda, Md.]: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some antiviral and antineoplastic drugs, and other pharmaceutical agents. Lyon, France: IARC, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Antineoplastic agents"

1

O'brien, Wendy Pott. "Antineoplastic Agents." In Physiologically Based Pharmacokinetic Modeling, 297–317. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2005. http://dx.doi.org/10.1002/0471478768.ch11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Patsalos, P. N. "Antineoplastic Agents." In Antiepileptic Drug Interactions, 319–32. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2434-4_57.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Patsalos, Philip N. "Antineoplastic Agents." In Antiepileptic Drug Interactions, 253–62. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-32909-3_61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Patsalos, Philip N. "Antineoplastic Agents." In Antiseizure Medication Interactions, 287–95. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-82790-8_68.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kirschenbaum, Harold L., and Michelle M. Kalis. "Antineoplastic Agents." In The Pharmacy Practice Handbook of Medication Facts, 319–56. New York: Routledge, 2023. http://dx.doi.org/10.4324/9780429272783-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Schmähl, D., M. R. Berger, B. K. Keppler, and T. Klenner. "New Antineoplastic Agents." In Cancer Therapy, 95–110. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74683-3_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bloch, Alexander. "Antineoplastic Agents and Cancer Cell Differentiation." In Cancer Biology and Therapeutics, 217–21. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4757-9564-6_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Jack, David B. "Pharmacokinetic data on antineoplastic and immunosuppressant agents." In Handbook of Clinical Pharmacokinetic Data, 44–49. London: Palgrave Macmillan UK, 1992. http://dx.doi.org/10.1007/978-1-349-22495-1_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Balis, Frank M. "The pharmacology of antineoplastic agents in children." In The Role of Pharmacology in Pediatric Oncology, 15–27. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-4267-7_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Berger, Martin R. "Experiments on the Carcinogenic Potential of Antineoplastic Agents." In Late Sequelae in Oncology, 263–71. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-46794-3_34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antineoplastic agents"

1

Alonso Castro, V., B. López Centeno, I. Martín Casasempere, D. Alioto, A. Gil Martín, M. Segura Bedmar, A. Aranguren Oyarzábal, and MJ Calvo Alcántara. "4CPS-105 Prescribed antineoplastic agents in paediatric patients." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.254.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yoon, Seug Yun, Namsu Lee, Sook-Ja Kim, Hee-Jeong Cheong, Kyoung Ha Kim, and Jong-Ho Won. "Abstract 3843: Pulmonary toxicities of molecular targeted antineoplastic agents." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-3843.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Labrèche, F., B. Roberge, A. Yennek, NJ Caron, and J.-F. Bussières. "1508 Is hospital sanitation personnel exposed to antineoplastic agents?" In 32nd Triennial Congress of the International Commission on Occupational Health (ICOH), Dublin, Ireland, 29th April to 4th May 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/oemed-2018-icohabstracts.923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Silva, Sâmela Maria de Oliveira, Manuelle de Araujo Holanda, Thaísa Mirella da Silva, Clebiana Alves e. silva Diniz, and Suzana Maria de Oliveira Costa Meneses. "Role of oncological nursing in stroke of antineoplastic drugs." In II INTERNATIONAL SEVEN MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/homeinternationalanais-044.

Full text

Abstract:

Abstract Exposure to antineoplastic drugs poses a potential risk to the health of professionals who handle, administer and dispose of them. The risk of harmful effects arising from exposure to the cytotoxic properties of antineoplastic agents is not restricted to patients, and health professionals may also experience cellular and clinical changes related to occupational exposure to these substances. Professional exposure can occur at any time during the handling of chemotherapy, whether in preparation, administration or disposal.

APA, Harvard, Vancouver, ISO, and other styles

5

Bradley, Cathy J., and Marcelo Coca Perraillon. "Abstract PR10: Fewer rural cancer patients treated with antineoplastic agents." In Abstracts: Eleventh AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 2-5, 2018; New Orleans, LA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp18-pr10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Trendowski, Matthew, Timothy D. Christen, Christopher Acquafondata, and Thomas P. Fondy. "Abstract 3802: Evaluation of microfilament-directed cytochalasins as novel antineoplastic agents." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3802.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Escudero-Vilaplana, V., R. Collado-Borrell, A. Giménez-Manzorro, C. Ortega-Navarro, E. Chamorro de Vega, C. Ruiz-Martínez, C. Rodríguez-González, A. Herranz-Alonso, and M. Sanjurjo-Sáez. "CP-163 Onco-haematological outpatients treated with oral antineoplastic agents: pharmacist interventions." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kulemina, Lidia V., Kevin Morgan, Daniil Shabashvili, Carmen Allegra, Min Chen, and Maria Zajac-Kaye. "Abstract 3892: Anti-cooperative allosteric inhibitors of thymidylate synthase as novel antineoplastic agents." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3892.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Narrillos-Moraza, A., V. Escudero-Vilaplana, R. Collado-Borrell, A. Hoyo-Muñoz, A. Gimenez-Manzorro, MA Amor-Garcia, S. Osorio-Prendes, A. Calles-Blanco, A. Herranz-Alonso, and M. Sanjurjo-Saez. "5PSQ-048 Analysis of drug interactions between oral antineoplastic agents and concurrent medications." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.365.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Rodriguez, A., X. Fernández, A. Arderiu, O. Fando, S. Pineda, J. Urbina, M. Berzosa, and D. Conde. "1ISG-003 Impact of telepharmacy and community pharmacy remote-dispensing on patients on oral antineoplastic agents." In 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antineoplastic agents"

1

Antineoplastic agents - occupational hazards in hospitals. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, September 2004. http://dx.doi.org/10.26616/nioshpub2004102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!